Almangush Alhadi, Pirinen Matti, Youssef Omar, Mäkitie Antti A, Leivo Ilmo
Department of Pathology, University of Helsinki, Helsinki, Finland.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Head Neck. 2020 Oct;42(10):3002-3017. doi: 10.1002/hed.26344. Epub 2020 Jun 17.
The eighth edition of the American Joint Committee on Cancer (AJCC8) staging manual has major changes in oral squamous cell carcinoma (OSCC). We searched PubMed, OvidMedline, Scopus, and Web of Science for studies that examined the performance of AJCC8 in OSCC. A total of 40 808 patients were included in the studies of our meta-analysis. A hazard ratio (HR) of 1.87 (95%CI 1.78-1.96) was seen for stage II, 2.65 (95%CI 2.51-2.80) for stage III, 3.46 (95%CI 3.31-3.61) for stage IVa, and 7.09 (95%CI 4.85-10.36) for stage IVb. A similar gradual increase in risk was noted for the N classification. For the T classification, however, there was a less clear variation in risk between T3 and T4. AJCC8 provides a good risk stratification for OSCC. Future research should examine the proposals introduced in the published studies to further improve the performance of AJCC8.
美国癌症联合委员会第八版（AJCC8）分期手册在口腔鳞状细胞癌（OSCC）方面有重大变化。我们在PubMed、OvidMedline、Scopus和Web of Science上检索了研究AJCC8在OSCC中表现的研究。我们的荟萃分析研究共纳入了40808例患者。II期的风险比（HR）为1.87（95%CI 1.78 - 1.96），III期为2.65（95%CI 2.51 - 2.80），IVa期为3.46（95%CI 3.31 - 3.61），IVb期为7.09（95%CI 4.85 - 10.36）。N分类的风险也有类似的逐渐增加。然而，对于T分类，T3和T4之间的风险差异不太明显。AJCC8为OSCC提供了良好的风险分层。未来的研究应检验已发表研究中提出的建议，以进一步提高AJCC8的性能。
